Oruka Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Oruka Therapeutics, Inc. (ORKA) had Debt Securities, Available-for-sale, Amortized Cost of $1.13 billion as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $1.13B.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $492.33M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $476.85M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $498.48M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $1.13B 10-Q · filed 2026-08-10 |
| 2026-03-31 | $492.33M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $476.85M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $498.48M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $349.38M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $368.84M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $384.36M 10-K · filed 2026-03-12 |
| 2017-12-31 | $3.05M 10-K · filed 2018-03-22 |
| 2017-09-30 | $7.81M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $6.91M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $13.05M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $16.13M 10-K · filed 2017-03-21 |
| 2016-09-30 | $19.35M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $16.97M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $6.21M 10-Q · filed 2016-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |